{"id":5780,"date":"2020-12-15T09:16:47","date_gmt":"2020-12-15T08:16:47","guid":{"rendered":"https:\/\/www.investincotedazur.com\/?p=5780"},"modified":"2023-02-10T14:07:46","modified_gmt":"2023-02-10T13:07:46","slug":"nice-innoskel-launches-with-e20-million-series-a-financing","status":"publish","type":"post","link":"https:\/\/www.investincotedazur.com\/en\/nice-innoskel-launches-with-e20-million-series-a-financing\/","title":{"rendered":"C\u00f4te d’Azur BioTech : InnoSkel Launches with \u20ac20 Million Series A Financing"},"content":{"rendered":"

InnoSkel, based in Nice C\u00f4te d’Azur<\/a> and Sophia Antipolis,\u00a0 is a newly launched platform biotechnology company<\/a> pioneering gene therapies for rare skeletal disease.<\/p>\n

The company announced that it has raised \u20ac20 million in a Series A financing round.<\/p>\n

The fundraise was co-led by Jeito Capital and Vida Ventures, with additional support from R\u00e9gion Sud Investissement and The Turenne Group. Proceeds from the financing will be used to advance the company\u2019s lead program clinical stage operations. InnoSkel was founded by Elvire Gouze, PhD, a scientific expert in skeletal disorders with over 20 years working in molecular pharmacology.<\/p>\n

InnoSkel is developing treatment options for a group of rare skeletal disorders collectively known as type 2 collagenopathies that affect the structure of the body\u2019s connective tissues (collagen). InnoSkel\u2019s lead asset, and initial point of focus, is a gene therapy for spondyloepiphyseal dysplasia congenita (SEDc), a type 2 collagenopathy that develops in infancy and affects approximately 1 in 100,000 individuals worldwide . SEDc is the second leading cause of dwarfism worldwide and is characterized by very short stature, severe skeletal and joint malformations, and abnormalities affecting the eyes and ears. The asset has demonstrated compelling efficacy in proof-of-concept studies conducted at the Institut de Biologie Valrose (iBV) of the University Cote d\u2019Azur, Nice, France.<\/p>\n

Elvire Gouze, Founder and CEO of InnoSkel<\/strong>, said: \u201cInnoskel is committed to developing transformative therapies for patients with skeletal dysplasia who currently have no viable treatment options and experience poor quality of life as a result. We are extremely excited to progress our novel gene therapy for SEDc, as well as our broader therapy platform, and will be working closely with the patient community as we move forwards.
\nWe are delighted to officially launch with the backing of top tier international healthcare investors Jeito Capital and Vida Ventures, which indicates the strength of Innoskel\u2019s platform. I would also like to personally recognize the iBV, the University Cote d\u2019Azur in Nice, as well as Inserm Transfert, for supporting InnoSkel in its mission and making its creation possible.\u201d<\/p>\n

In addition to pre-clinical research, the funds will allow InnoSkel to further develop its broader asset pipeline targeting novel therapies for a range of rare skeletal disorders where there is severe unmet medical need. There are more than 350 of these disorders. InnoSkel also intends to use the funds to expand its management and laboratory teams internationally.<\/p>\n

Rafa\u00e8le Tordjman, Founder and CEO at Jeito<\/strong>, said: \u201cOur investment in InnoSkel aligns with Jeito\u2019s mission of supporting companies with high-quality science, potential for acceleration, and tackling real unmet needs. We are confident that Innoskel CEO Elvire Gouze will lead the company from strength to strength as it progresses towards clinical stage.\u201d<\/p>\n

Rajul Jain, MD, Director of Vida Ventures<\/strong>, said: \u201cWe share InnoSkel\u2019s commitment to advancing novel therapies that will translate into effective treatments for patients in areas of unmet medical need. Dr. Gouze and her outstanding team have a deep understanding of the development of treatments for patients with rare skeletal disorders, and we are delighted to support them as they advance this important technology into the clinic.\u201d<\/p>\n

\"\"\u00a0\"\"\u00a0\"\"\u00a0\"\"<\/p>\n

About Dr. Elvire Gouze, CEO and Founder of InnoSkel<\/h4>\n

InnoSkel is led by Elvire Gouze, an experienced scientist, serial entrepreneur and expert in skeletal disorders. She holds a PhD in Molecular Pharmacology and has over 20 years of experience in bone and cartilage diseases. Dr. Gouze has a proven track record of progressing the development of an innovative therapeutic pipeline, as seen with her first venture TherAchon, a biotech company focusing on achondroplasia, a rare bone disease, which was acquired at Phase 1 stage for $810m by Pfizer in mid-2019. From 2016, Dr. Gouze was team leader at the Institute de Biologie Valrose in Nice where her team focused on the development of innovative biotherapies for skeletal dysplasia.<\/p>\n

About InnoSkel<\/h4>\n

InnoSkel is a pioneering platform biotechnology company developing therapies for rare skeletal diseases. InnoSkel is developing treatment options for a group of rare skeletal disorders collectively known as type 2 collagenopathies, the most severe of which is Spondyloepiphyseal Dysplasia congenita (SEDc), the second leading cause of dwarfism worldwide. InnoSkel\u2019s lead gene therapy asset for SEDc has demonstrated good efficacy in proof-of-concept studies. The company\u2019s fundamental mission is to improve the lives of patients living with skeletal dysplasia and to answer their unmet needs, keeping their voices at the heart of all they do. InnoSkel is a spin-out of the Institut de Biologie Valrose at Inserm, the French National Institute of Health and Medical Research, and is based in Nice, France.<\/p>\n

For more information, visit\u00a0www.innoskel.com<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

InnoSkel, based in Nice C\u00f4te d’Azur and Sophia Antipolis,\u00a0 is a newly launched platform biotechnology company pioneering gene therapies for rare skeletal disease. The company announced that it has raised \u20ac20 million in a Series A financing round. The fundraise was co-led by Jeito Capital and Vida Ventures, with additional support from R\u00e9gion Sud Investissement […]<\/p>\n","protected":false},"author":19,"featured_media":5782,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"categories":[96,102],"tags":[],"acf":[],"yoast_head":"\nNice : Biotech company Innoskel raises \u20ac20 millions - Invest in C\u00f4te d'Azur<\/title>\n<meta name=\"description\" content=\"InnoSkel, based in Nice C\u00f4te d'Azur,\u00a0 is a newly launched platform biotechnology company pioneering gene therapies for rare skeletal disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.investincotedazur.com\/en\/nice-innoskel-launches-with-e20-million-series-a-financing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nice : Biotech company Innoskel raises \u20ac20 millions - Invest in C\u00f4te d'Azur\" \/>\n<meta property=\"og:description\" content=\"InnoSkel, based in Nice C\u00f4te d'Azur,\u00a0 is a newly launched platform biotechnology company pioneering gene therapies for rare skeletal disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.investincotedazur.com\/en\/nice-innoskel-launches-with-e20-million-series-a-financing\/\" \/>\n<meta property=\"og:site_name\" content=\"Invest in C\u00f4te d'Azur\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-15T08:16:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-10T13:07:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.investincotedazur.com\/wp-content\/uploads\/2020\/12\/innoskel-nice.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"495\" \/>\n\t<meta property=\"og:image:height\" content=\"352\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sophie Duchaussoy\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Investcotedazur\" \/>\n<meta name=\"twitter:site\" content=\"@Investcotedazur\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sophie Duchaussoy\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.investincotedazur.com\/en\/nice-innoskel-launches-with-e20-million-series-a-financing\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.investincotedazur.com\/en\/nice-innoskel-launches-with-e20-million-series-a-financing\/\"},\"author\":{\"name\":\"Sophie Duchaussoy\",\"@id\":\"https:\/\/www.investincotedazur.com\/en\/#\/schema\/person\/cec71af3eade406c5cf7d97983a1b1e1\"},\"headline\":\"C\u00f4te d’Azur BioTech : InnoSkel Launches with \u20ac20 Million Series A Financing\",\"datePublished\":\"2020-12-15T08:16:47+00:00\",\"dateModified\":\"2023-02-10T13:07:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.investincotedazur.com\/en\/nice-innoskel-launches-with-e20-million-series-a-financing\/\"},\"wordCount\":771,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.investincotedazur.com\/en\/#organization\"},\"articleSection\":[\"HealthTech\",\"Nice C\u00f4te d'Azur Metropolis\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.investincotedazur.com\/en\/nice-innoskel-launches-with-e20-million-series-a-financing\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.investincotedazur.com\/en\/nice-innoskel-launches-with-e20-million-series-a-financing\/\",\"url\":\"https:\/\/www.investincotedazur.com\/en\/nice-innoskel-launches-with-e20-million-series-a-financing\/\",\"name\":\"Nice : Biotech company Innoskel raises \u20ac20 millions - Invest in C\u00f4te d'Azur\",\"isPartOf\":{\"@id\":\"https:\/\/www.investincotedazur.com\/en\/#website\"},\"datePublished\":\"2020-12-15T08:16:47+00:00\",\"dateModified\":\"2023-02-10T13:07:46+00:00\",\"description\":\"InnoSkel, based in Nice C\u00f4te d'Azur,\u00a0 is a newly launched platform biotechnology company pioneering gene therapies for rare skeletal disease.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.investincotedazur.com\/en\/nice-innoskel-launches-with-e20-million-series-a-financing\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.investincotedazur.com\/en\/#website\",\"url\":\"https:\/\/www.investincotedazur.com\/en\/\",\"name\":\"Invest in C\u00f4te d'Azur\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.investincotedazur.com\/en\/#organization\"},\"alternateName\":\"Invest in C\u00f4te d'Azur\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.investincotedazur.com\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.investincotedazur.com\/en\/#organization\",\"name\":\"Invest in C\u00f4te d'Azur\",\"alternateName\":\"Invest in C\u00f4te d'Azur\",\"url\":\"https:\/\/www.investincotedazur.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.investincotedazur.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.investincotedazur.com\/wp-content\/uploads\/2023\/05\/cropped-New-missions-3.png\",\"contentUrl\":\"https:\/\/www.investincotedazur.com\/wp-content\/uploads\/2023\/05\/cropped-New-missions-3.png\",\"width\":512,\"height\":512,\"caption\":\"Invest in C\u00f4te d'Azur\"},\"image\":{\"@id\":\"https:\/\/www.investincotedazur.com\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/investincotedazur\/\",\"https:\/\/twitter.com\/Investcotedazur\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.investincotedazur.com\/en\/#\/schema\/person\/cec71af3eade406c5cf7d97983a1b1e1\",\"name\":\"Sophie Duchaussoy\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.investincotedazur.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/aa7401b68647f02c9e59459ba6ccd73c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/aa7401b68647f02c9e59459ba6ccd73c?s=96&d=mm&r=g\",\"caption\":\"Sophie Duchaussoy\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nice : Biotech company Innoskel raises \u20ac20 millions - Invest in C\u00f4te d'Azur","description":"InnoSkel, based in Nice C\u00f4te d'Azur,\u00a0 is a newly launched platform biotechnology company pioneering gene therapies for rare skeletal disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.investincotedazur.com\/en\/nice-innoskel-launches-with-e20-million-series-a-financing\/","og_locale":"en_US","og_type":"article","og_title":"Nice : Biotech company Innoskel raises \u20ac20 millions - Invest in C\u00f4te d'Azur","og_description":"InnoSkel, based in Nice C\u00f4te d'Azur,\u00a0 is a newly launched platform biotechnology company pioneering gene therapies for rare skeletal disease.","og_url":"https:\/\/www.investincotedazur.com\/en\/nice-innoskel-launches-with-e20-million-series-a-financing\/","og_site_name":"Invest in C\u00f4te d'Azur","article_published_time":"2020-12-15T08:16:47+00:00","article_modified_time":"2023-02-10T13:07:46+00:00","og_image":[{"width":495,"height":352,"url":"https:\/\/www.investincotedazur.com\/wp-content\/uploads\/2020\/12\/innoskel-nice.jpg","type":"image\/jpeg"}],"author":"Sophie Duchaussoy","twitter_card":"summary_large_image","twitter_creator":"@Investcotedazur","twitter_site":"@Investcotedazur","twitter_misc":{"Written by":"Sophie Duchaussoy","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.investincotedazur.com\/en\/nice-innoskel-launches-with-e20-million-series-a-financing\/#article","isPartOf":{"@id":"https:\/\/www.investincotedazur.com\/en\/nice-innoskel-launches-with-e20-million-series-a-financing\/"},"author":{"name":"Sophie Duchaussoy","@id":"https:\/\/www.investincotedazur.com\/en\/#\/schema\/person\/cec71af3eade406c5cf7d97983a1b1e1"},"headline":"C\u00f4te d’Azur BioTech : InnoSkel Launches with \u20ac20 Million Series A Financing","datePublished":"2020-12-15T08:16:47+00:00","dateModified":"2023-02-10T13:07:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.investincotedazur.com\/en\/nice-innoskel-launches-with-e20-million-series-a-financing\/"},"wordCount":771,"commentCount":0,"publisher":{"@id":"https:\/\/www.investincotedazur.com\/en\/#organization"},"articleSection":["HealthTech","Nice C\u00f4te d'Azur Metropolis"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.investincotedazur.com\/en\/nice-innoskel-launches-with-e20-million-series-a-financing\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.investincotedazur.com\/en\/nice-innoskel-launches-with-e20-million-series-a-financing\/","url":"https:\/\/www.investincotedazur.com\/en\/nice-innoskel-launches-with-e20-million-series-a-financing\/","name":"Nice : Biotech company Innoskel raises \u20ac20 millions - Invest in C\u00f4te d'Azur","isPartOf":{"@id":"https:\/\/www.investincotedazur.com\/en\/#website"},"datePublished":"2020-12-15T08:16:47+00:00","dateModified":"2023-02-10T13:07:46+00:00","description":"InnoSkel, based in Nice C\u00f4te d'Azur,\u00a0 is a newly launched platform biotechnology company pioneering gene therapies for rare skeletal disease.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.investincotedazur.com\/en\/nice-innoskel-launches-with-e20-million-series-a-financing\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.investincotedazur.com\/en\/#website","url":"https:\/\/www.investincotedazur.com\/en\/","name":"Invest in C\u00f4te d'Azur","description":"","publisher":{"@id":"https:\/\/www.investincotedazur.com\/en\/#organization"},"alternateName":"Invest in C\u00f4te d'Azur","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.investincotedazur.com\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.investincotedazur.com\/en\/#organization","name":"Invest in C\u00f4te d'Azur","alternateName":"Invest in C\u00f4te d'Azur","url":"https:\/\/www.investincotedazur.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.investincotedazur.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.investincotedazur.com\/wp-content\/uploads\/2023\/05\/cropped-New-missions-3.png","contentUrl":"https:\/\/www.investincotedazur.com\/wp-content\/uploads\/2023\/05\/cropped-New-missions-3.png","width":512,"height":512,"caption":"Invest in C\u00f4te d'Azur"},"image":{"@id":"https:\/\/www.investincotedazur.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/investincotedazur\/","https:\/\/twitter.com\/Investcotedazur"]},{"@type":"Person","@id":"https:\/\/www.investincotedazur.com\/en\/#\/schema\/person\/cec71af3eade406c5cf7d97983a1b1e1","name":"Sophie Duchaussoy","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.investincotedazur.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/aa7401b68647f02c9e59459ba6ccd73c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/aa7401b68647f02c9e59459ba6ccd73c?s=96&d=mm&r=g","caption":"Sophie Duchaussoy"}}]}},"_links":{"self":[{"href":"https:\/\/www.investincotedazur.com\/en\/wp-json\/wp\/v2\/posts\/5780"}],"collection":[{"href":"https:\/\/www.investincotedazur.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.investincotedazur.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.investincotedazur.com\/en\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"https:\/\/www.investincotedazur.com\/en\/wp-json\/wp\/v2\/comments?post=5780"}],"version-history":[{"count":3,"href":"https:\/\/www.investincotedazur.com\/en\/wp-json\/wp\/v2\/posts\/5780\/revisions"}],"predecessor-version":[{"id":13980,"href":"https:\/\/www.investincotedazur.com\/en\/wp-json\/wp\/v2\/posts\/5780\/revisions\/13980"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.investincotedazur.com\/en\/wp-json\/wp\/v2\/media\/5782"}],"wp:attachment":[{"href":"https:\/\/www.investincotedazur.com\/en\/wp-json\/wp\/v2\/media?parent=5780"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.investincotedazur.com\/en\/wp-json\/wp\/v2\/categories?post=5780"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.investincotedazur.com\/en\/wp-json\/wp\/v2\/tags?post=5780"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}